Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Charta Health

Charta Health raises $55M to sell the same chart-review AI to insurers and providers

Insight Partners led the Series B, bringing Charta's total to $85 million. The company is launching separate products for providers and health plans that it says share a single AI engine.

Charted Staff2 min read
From a company announcement published Nov. 10, 2026, and Elevance Health's third-quarter earnings release furnished to the SEC on Oct. 21, 2026
A medical records clerk at Naval Branch Health Clinic Jacksonville retrieves a patient's record for review in August 2022.
A medical records clerk at Naval Branch Health Clinic Jacksonville retrieves a patient's record for review in August 2022. File photo.U.S. Navy (public domain)
Amount
$55M
Type
Series B
Company
Charta Health
Lead investor
Insight Partners
Sector
Health AI
Announced
Nov. 10, 2026

A health plan and a provider can read one medical chart with different software, disagree about the coding and then trade denials and appeals, Charta Health says. Its answer is to sell one AI to both camps, and it said Nov. 10 that Insight Partners led a $55 million Series B to pay for that push.

Existing investors Madrona, Bain Capital Ventures and South Park Commons participated, along with QuantumLight. Charta said it has now raised $85 million in all, across three financings in under two years. It did not disclose a valuation.

Why it matters: Payers and providers are both adopting AI, and Charta argues that has deepened the fight over coding rather than settling it. It cited a 2025 study, which it did not name, that put the 2023 cost of claims adjudication for hospitals and health systems at over $25 billion, with close to $18 billion potentially wasted on denials and appeals.

Two product lines

Charta for Providers checks every chart against payer rules, coding guidelines and each organization's clinical protocols before a claim is sent, then shows its findings for human sign-off in the EHR, the company said. Customers named in the release include American Family Care, Grow Therapy and Pediatric Associates Family of Companies.

Charta for Payers, launched alongside the round, bundles six products for health plans. They cover retrospective coding of hierarchical condition categories, or HCCs, which feed risk adjustment; a second pass of coding automated by AI; a coding platform; tools for prospective risk adjustment; HCC validation and audit workflows; and detection of HEDIS quality and care gaps.

Charta said it built the payer suite with one of the largest U.S. health insurers, which it did not name, and that it serves plans in Medicare Advantage and the ACA Marketplace.

The money at stake in risk adjustment data showed up in an insurer's results this fall. Elevance Health, which Charta's release does not mention, said in October that its full-year GAAP outlook includes a $4.28-a-share accrual for potential exposure tied to certain historical Medicare Advantage risk adjustment data, related to a CMS notice.

"When every chart gets reviewed, accuracy stops being a guess," Justin Liu, Charta's chief executive and co-founder, said in the announcement.

Jeff Horing, an Insight Partners co-founder and managing director, put the investment case in terms of the record itself. "As payers and providers both adopt AI, we believe the opportunity lies in getting the underlying record, or the 'ground truth,' right before a claim is submitted," Horing said.

The founders

Liu and Scott Morris, the chief technology officer, came to Charta from Rockset, which the company said became OpenAI's first product acquisition. Before starting Charta, the two spent a year earning the Certified Professional Coder credential and interviewed over 100 health care leaders, the company said. Charta now has its engineers and growth staff earn medical coding certifications as well.

The company said revenue grew tenfold over the past 12 months, with gains among provider groups and health plans alike, without giving figures.

Charta said it will spend the money on AI research and development, the two product launches and moving its provider product into new specialties. It did not say which specialties come next.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.